Company intelligence / Profile preview

Nucleomed

Oxford, England, United Kingdomnucleomed.org ↗

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

Nucleome has developed a proprietary genomics and machine learning platform to identify first-in-class drug targets from the non-coding genome. Their lead program, an antibody targeting T-regulatory cell function for rheumatoid arthritis and other autoimmune diseases, will enter clinical trials at the start of 2027. The company has mapped genes to genetics in human immune cells and discovered several potential first-in-class autoimmune disease targets.

Therapeutic areas: Immunology
Modalities: AntibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Nucleomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleomed.

Explore the full profile